Mukka Proteins Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2026.
MUKKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mukka Proteins reported strong full-year FY26 consolidated results with total income of ₹14,781.35 million (up ~44% YoY) and revenue from operations at ₹14,035.15 million (up ~43% YoY from ₹9,800.26 million). Net profit after tax stood at ₹570.86 million (standalone: ₹424.12 million), growing ~19% on consolidated basis. The auditors issued an unmodified (clean) opinion on both standalone and consolidated financials. The Board approved raising ₹75 crore via secured NCD issuances (₹25 crore + ₹50 crore) on a private placement basis. New investments include a 51% stake in partnership firm MPL FC HRC JV (₹2.55 lakh capital contribution) and incorporation of an overseas entity Lanka Bio Proteins Private Limited in Sri Lanka (₹2.5 crore for 49% stake). Operating cash flow remained deeply negative at –₹1,112.65 million (consolidated) driven by a massive ₹2,923 million surge in inventories. Total borrowings grew sharply to ₹7,677.70 million (standalone: ₹6,699.87 million), reflecting aggressive working capital and capex buildup.
Revenue growth is impressive at ~43%, but the sharp rise in borrowings and persistent negative operating cash flow raise concerns about liquidity risk. The NCD issuance of ₹75 crore signals ongoing funding needs. Shareholders should watch inventory buildup and debt levels closely as the company scales operations.